MAOB

Across TCGA pan-cancer cohorts, MAOB mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAOB data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MAOB mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MAOB expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, GBM, and HNSC are the cancer types where MAOB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.659	0.331	<.001	91	view →
GBM	OS	Median	All	0.378	0.666	<.001	36	view →
HNSC	OS	Quartile	IV	0.629	0.969	.012	13	view →
CCRCC	DFS	Median	All	0.637	0.834	.019	6	view →
LSCC	OS	Quartile	II,III,IV	0.753	1.000	.043	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAOB–PDAC (OS)

Open the PDAC breakdown →